Pyridostigmine Shortage: What Providers and Prescribers Need to Know in 2026

Patients with myasthenia gravis (MG) and postural orthostatic tachycardia syndrome (POTS) who rely on Pyridostigmine Bromide (Mestinon) for symptom control have been experiencing supply disruptions since mid-2024. As of 2026, the 180 mg extended-release (ER) formulation remains the most affected, with generic manufacturers Alvogen and Rising Pharmaceuticals on back order.

This clinical summary covers the current supply landscape, formulation conversion guidance, and alternative management strategies to help you support your patients through this ongoing shortage.

Current Supply Landscape (2026)

As of early 2026, the FDA has not placed Pyridostigmine Bromide on its official Drug Shortage Database. However, the supply situation for the ER formulation is clinically significant:

Pyridostigmine ER 180 mg generic: Back-ordered from multiple generic manufacturers since mid-2024. No confirmed release date as of early 2026.

Brand-name Mestinon Timespan 180 mg (Bausch Health): More consistently available. However, the list price exceeds $800 for 30 tablets, creating access barriers for uninsured or underinsured patients.

Pyridostigmine IR 60 mg generic: Generally available with no reported systemic shortage. Retail cash price ranges from $75–$125 for 90 tablets; significantly lower with discount cards.

Oral solution (60 mg/5 mL): Available but may require special ordering at many retail pharmacies.

Formulation Conversion: ER 180 mg to IR 60 mg

For patients who cannot obtain the 180 mg ER tablets, conversion to the immediate-release formulation is the most practical short-term strategy. Key considerations:

Approximate equivalence: One 180 mg ER tablet is approximately equivalent to three 60 mg IR tablets taken over the same period. The immediate effect of a 180 mg Timespan tablet approximates a 60 mg conventional tablet, but its duration averages 2.5 times longer.

Dosing frequency: IR tablets are typically dosed every 3–6 hours while awake. Starting dose is often 60 mg three times daily, adjusted based on symptom response and tolerability.

Side effect profile: Some patients experience more gastrointestinal side effects (nausea, cramping, diarrhea) with the IR formulation due to peak concentration effects. Consider starting at the lower end of the dosing range and titrating.

Monitor closely: Reassess muscle strength and functional status within 1–2 weeks after the formulation switch. Cholinergic symptoms (excessive secretions, fasciculations, bradycardia, worsening weakness) should prompt dose reduction.

Clinical Warning: Cholinergic Crisis Risk

Overdosage of Pyridostigmine can result in cholinergic crisis, which is characterized by paradoxical increasing muscle weakness — potentially involving respiratory muscles. This can be clinically indistinguishable from myasthenic crisis. If a patient presents with worsening weakness after a dose increase or formulation switch, consider both possibilities. A Tensilon (edrophonium) test may help differentiate the two, though this test requires careful patient selection and monitoring.

When to Consider Escalating Therapy

If a patient cannot tolerate the IR formulation, cannot afford or access brand-name Mestinon Timespan, and cannot find ER generics, consider whether disease-modifying therapy is warranted or should be optimized:

Corticosteroids (prednisone): Effective in 66–85% of MG patients. Important caveat: transient worsening of weakness can occur in the first 1–4 weeks of starting corticosteroids. Initiate with caution and consider hospitalization for patients with severe disease. Withdraw anticholinesterase agents at least 24 hours before starting corticosteroids if possible.

Azathioprine (Imuran): Steroid-sparing immunosuppressant for long-term management. Onset of effect is 6–12 months. Not a rapid intervention during a shortage, but appropriate for patients where long-term disease modification is needed.

Biologics (efgartigimod alfa/Vyvgart, eculizumab/Soliris, ravulizumab/Ultomiris): FDA-approved for anti-AChR antibody-positive generalized MG. Consider for patients with inadequate control or who need reduced dependence on cholinesterase inhibitors.

38,803+ patients found their medications in stock

38K+

Find Pyridostigmine In Stock Today →

Insurance and Prior Authorization Considerations

If a patient cannot obtain generic Pyridostigmine ER, prescribing brand-name Mestinon Timespan may require a prior authorization (PA) or step therapy override from their insurer. When submitting PA requests during a shortage:

Document the patient's medical necessity for the ER formulation (e.g., GI intolerance of IR, nocturnal symptom control needs, compliance concerns with frequent dosing)

Include documentation that generic ER is unavailable at local pharmacies

Bausch Health's Patient Assistance Program (bauschhealthpap.com) can provide brand-name Mestinon Timespan at no cost for eligible uninsured or underinsured patients

Helping Your Patients Find Their Medication

Directing patients to medfinder.com/providers can help. medfinder contacts pharmacies near the patient to identify which ones have their specific formulation in stock, reducing the burden on patients who may have limited energy or mobility due to their condition.

For patient-facing information, our 2026 Pyridostigmine shortage update for patients covers practical steps in plain language.